IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.088
AS - Asia 2.329
EU - Europa 1.514
SA - Sud America 556
AF - Africa 151
OC - Oceania 2
Totale 8.640
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.996
SG - Singapore 784
BR - Brasile 454
VN - Vietnam 440
RU - Federazione Russa 433
CN - Cina 382
HK - Hong Kong 359
IE - Irlanda 274
IT - Italia 221
SE - Svezia 165
FR - Francia 129
GB - Regno Unito 96
BD - Bangladesh 73
IN - India 68
CI - Costa d'Avorio 65
DE - Germania 58
CA - Canada 35
IQ - Iraq 35
MX - Messico 35
AR - Argentina 32
FI - Finlandia 30
ZA - Sudafrica 29
TR - Turchia 23
JP - Giappone 21
NL - Olanda 19
PK - Pakistan 19
PL - Polonia 19
UZ - Uzbekistan 19
CO - Colombia 17
UA - Ucraina 17
VE - Venezuela 17
AT - Austria 16
EC - Ecuador 14
ID - Indonesia 14
MA - Marocco 14
DZ - Algeria 13
AE - Emirati Arabi Uniti 11
JO - Giordania 9
MY - Malesia 9
CL - Cile 8
ES - Italia 8
PH - Filippine 8
SA - Arabia Saudita 8
TN - Tunisia 8
KE - Kenya 7
KR - Corea 6
LT - Lituania 6
NP - Nepal 6
IL - Israele 5
KG - Kirghizistan 5
PY - Paraguay 5
TH - Thailandia 5
AZ - Azerbaigian 4
BO - Bolivia 4
JM - Giamaica 4
KZ - Kazakistan 4
NG - Nigeria 4
SV - El Salvador 4
BE - Belgio 3
BH - Bahrain 3
HN - Honduras 3
NI - Nicaragua 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
LK - Sri Lanka 2
PE - Perù 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AU - Australia 1
BF - Burkina Faso 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
SI - Slovenia 1
Totale 8.639
Salva come PNG Salva come JPEG
Città #
Ashburn 1.301
Singapore 448
Hong Kong 352
San Jose 317
Chandler 297
Dublin 273
Dallas 177
Boardman 158
Ho Chi Minh City 147
The Dalles 126
Fairfield 124
Hanoi 108
Lauterbourg 104
Lawrence 104
Princeton 104
Beijing 100
New York 89
Moscow 76
Abidjan 65
Los Angeles 64
San Diego 59
Washington 53
Council Bluffs 52
Des Moines 49
São Paulo 47
Milan 36
London 32
Seattle 32
Santa Clara 30
Munich 26
Da Nang 25
Turin 24
Redmond 21
Columbus 20
Houston 20
Chennai 19
Tokyo 19
Chicago 18
Haiphong 18
Rio de Janeiro 18
Tashkent 18
Orem 16
Johannesburg 15
Turku 15
Baghdad 14
Frankfurt am Main 14
Montreal 14
Boston 13
Hefei 13
Shanghai 13
Amsterdam 12
Brooklyn 12
Helsinki 12
Warsaw 12
Brasília 11
Guangzhou 11
Mexico City 11
Pune 11
Salt Lake City 11
Vienna 11
Belo Horizonte 10
Miano 10
San Francisco 10
Ancona 9
Cambridge 9
Manchester 9
Woodbridge 9
Nuremberg 8
Phoenix 8
Ribeirão Preto 8
Atlanta 7
Biên Hòa 7
Buffalo 7
Dhaka 7
Elk Grove Village 7
Fortaleza 7
Jakarta 7
Mumbai 7
Nha Trang 7
Poplar 7
Porto Alegre 7
Toronto 7
Amman 6
Ankara 6
Denver 6
Karachi 6
Nairobi 6
Recife 6
Salvador 6
Thái Bình 6
Bishkek 5
Bologna 5
Campinas 5
Can Tho 5
Changsha 5
Charlotte 5
Contagem 5
Curitiba 5
Detroit 5
Guayaquil 5
Totale 5.683
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 166
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 144
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 125
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 120
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 115
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 115
Sorafenib for the treatment of breast cancer 112
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 111
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 109
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 108
The application of cancer stem cell model in malignant mesothelioma 108
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 105
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 104
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 104
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 103
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 102
Cancer and the microbiome: Potential applications as new tumor biomarker 101
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 101
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 101
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 100
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 98
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 97
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 95
Bortezomib: A new pro-apoptotic agent in cancer treatment 95
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 95
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 94
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 94
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 93
VIPoma and PPoma 93
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 93
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 91
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 89
New generation anaplastic lymphoma kinase inhibitors 89
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 88
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 88
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 87
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 86
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 85
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 85
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 84
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 84
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 84
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 84
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 83
A headlight on liquid biopsies: a challenging tool for breast cancer management 82
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 81
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 80
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 78
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 77
How much of familial breast cancer risk is currently explained by the known genes? 77
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 75
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 75
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 75
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 75
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 74
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 73
Fully human antibodies for malignant pleural mesothelioma targeting 72
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 72
The role of targeted therapy for gastrointestinal tumors 71
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 71
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 71
Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy 69
Monoclonal antibodies in gastrointestinal cancers 69
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 69
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 69
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 68
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 67
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 66
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 66
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 64
Dietary restriction: could it be considered as speed bump on tumor progression road? 64
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 63
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 62
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 61
EGFR genomic alterations in cancer: prognostic and predictive values 61
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 61
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 61
Well-being among Italian medical oncologists: An exploratory study 61
Anti-endothelin drugs in solid tumors 61
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 61
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach? 60
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 60
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 59
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 58
Sex steroids, carcinogenesis, and cancer progression 58
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 58
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 57
Ramucirumab and its use in gastric cancer treatment 57
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 57
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 57
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 57
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 57
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 57
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 56
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 56
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 56
Multisciplinary management of patients with liver metastasis from colorectal cancer 54
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 54
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 53
Targeted therapies in hepatocellular carcinoma 53
Totale 8.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.205
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.205
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024846 157 17 79 122 158 185 18 27 0 9 20 54
2024/20251.794 91 176 29 43 59 138 238 87 472 103 148 210
2025/20264.577 264 227 182 290 479 319 923 507 488 471 243 184
Totale 8.848